SCHEMBL352410

SCHEMBL352410

CCO[CH][SiH3]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676463 0.72
SCHEMBL8052611 0.67
SCHEMBL12226 0.67
SCHEMBL1407388 0.67
SCHEMBL1407387 0.67
Ethoxycarbonyl Group SCHEMBL27767802 0.65
SCHEMBL209 0.64
SCHEMBL6109145 0.64 CASP1 (0.30)
SCHEMBL2957555 0.64
SCHEMBL27303540 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113454212-A Modified terminal deoxynucleotidyl transferase (TdT) 纽克莱生物科技有限公司 2021-09-28 CN claimed
CN-110603038-A Rapamycin analogs 塔姆山治疗公司 2019-12-20 CN claimed
CN-101044138-A Indazole compounds and their use as herbicides PFIZER (US) 2007-09-26 CN claimed
CN-1149296-A Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them AMERICAN HOME PROD (US) 1997-05-07 CN claimed
CN-113840929-B Oligonucleotide synthesis method 核蛋白有限公司 2024-06-04 CN disclosed
WO-2024052692-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
WO-2024052701-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
WO-2024052690-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
WO-2024052702-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
EP-4301752-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2024-01-10 EP disclosed
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-01-09 US disclosed
CN-117295736-A Benzo [ C ] [2,6] naphthyridine derivatives, compositions thereof and therapeutic uses thereof 剑桥实业有限公司 2023-12-26 CN disclosed
CN-1059905-C Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them AMERICAN HOME PROD (US) 2000-12-27 CN disclosed
US-6143743-A TREATMENT OF NERVOUS SYSTEM DISORDERS DUPONT PHARMACEUTICALS COMPANY (US) 2000-11-07 US disclosed
EP-0994877-A1 IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Du Pont Pharmaceuticals Company (US) 2000-04-26 EP disclosed
WO-1999001454-A1 IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS DU PONT PHARMACEUTICALS COMPANY (US) 1999-01-14 WO disclosed
CN-1202887-A Tetrahydroquinolines as NMDA antagonists GLAXO WELLCOME SPA (IT) 1998-12-23 CN disclosed
CN-1149296-A Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them AMERICAN HOME PROD (US) 1997-05-07 CN disclosed
CN-1095379-A Condensed heterocyclic derivates and weedicide KUMIAI CHEMICAL INDUSTRY CO (JP) 1994-11-23 CN disclosed
US-5084567-A Electroconductive charge transfer compounds CIBA-GEIGY CORPORATION (US) 1992-01-28 US disclosed